Investors sue 89bio, Barinthus Biotherapeutics, and Roche over merger deal.

Brodsky & Smith is investigating 89bio's acquisition by Roche for $14.50 per share, plus a non-tradeable CVR of up to $6.00 per share. The investigation concerns whether the 89bio Board breached its fiduciary duties by failing to conduct a fair process and ensuring fair value for shareholders. Shareholders who wish to discuss the investigation can contact Jason Brodsky or Marc Ackerman at 855-576-4847.

Roche (RHHBY, RO.SW, ROG.SW) has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB) at $14.50 per share, plus a non-tradeable contingent value right (CVR) that could provide additional milestone-based payments of up to $6.00 per share Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR^[1]. The offer is being made pursuant to a previously announced merger agreement dated September 17, 2025 Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR^[1].

However, Halper Sadeh LLC, an investor rights law firm, is investigating the transaction, alleging potential violations of federal securities laws and breaches of fiduciary duties by the 89bio Board SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders^[2]. The investigation concerns whether the Board failed to conduct a fair process and ensure fair value for shareholders. Shareholders who wish to discuss the investigation can contact Jason Brodsky or Marc Ackerman at 855-576-4847 SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders^[2].

The tender offer period will expire on October 29, 2025, unless extended. Roche's acquisition of 89bio, a biotechnology company focused on the development of cell therapies, is expected to enhance Roche's capabilities in this area Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR^[1]. The CVR component of the offer provides an additional layer of potential value to shareholders, contingent on the achievement of specified milestones.

Investors and shareholders are advised to carefully review the terms of the offer and consider seeking legal advice if they have concerns about the fairness and value of the transaction. The investigation by Halper Sadeh LLC highlights the importance of transparency and fairness in corporate acquisitions, particularly in the biotechnology sector.